by Since angiogenesis is a requirement for tumor growth, an argument can be made that suppressing angiogenesis benefits oHSVs directly. A few of the oHSVs generated have shown antiangiogenic effects on their own. with the observation that patients with cancer and a viral infection could, on the rare occasion, briefly enter cancer remission. 1Although such cases were noted as early as the mid-1800s (before viruses were known to exist), it was not until the 1950s and 1960s that an earnest effort was mounted KILLER to put this observation into practice. Clinical trials using different human viruses including hepatitis, 2EpsteinBarr, 3adenovirus, 4and Defactinib hydrochloride rabies5were undertaken with mixed results. None of the studies were able to overcome the risk that infecting humans with wild type virus posed. Attempts were also made to identify and adapt animal viruses for oncolytic virotherapy. Animal viruses that lacked pathogenicity in normal human tissue, yet still retained a propensity for replicating in human cancer cells, were identified in order to circumvent the side effects of human oncolytic viruses. However , the potential for these viruses to alter their tropism to normal human cells was an impediment that halted the majority of virotherapy research with animal viruses. 6 Interest in oncolytic virotherapy was reborn in the 1990s with the advent of genetic engineering. Combined with the extensive knowledge that had been accumulated on viruses, genetic engineering allowed the generation of viruses with specific attenuations. The deletion of viral genes that, while essential for replication in normal tissue, were not required for replication in cancerous cells, allowed viruses to be retargeted toward cancer cells. Herpes simplex virus (HSV)7was identified as a highly attractive candidate for oncolytic virotherapy due to several characteristics including: 1) a naturally cytolytic life cycle with the ability to infect a broad range of cell types; 2) a highly prevalent human pathogen which in the vast majority of cases causes a self-limiting disease that can be treated with antivirals in life-threatening cases; 3) a very large genome, with many nonessential genes that can be replaced with foreign genes; and 4) an envelope with separate attachment and fusion glycoproteins which can Defactinib hydrochloride be modified for improved cancer cell targeting. The initial focus of oncolytic HSV (oHSV) virotherapy involved demonstrating the safety of oHSVs for the treatment of cancer. Subsequent research has focused on confirming that oHSV mutants can be effective in various cancers and enhanced by targeting areas such as host immunity, tumor microenvironment, and cancer-specific cell functions, Defactinib hydrochloride either by insertion of human genes into the oHSV and/or combining with other therapies. This has culminated in the approval by the US Food and Drug Administration (FDA) of the oHSV talimogene laherparepvec (T-VEC) for the treatment of melanoma. 810This review highlights the development of oHSV for the treatment of cancers and potential improvements for the activity and use of oHSV. For a perspective, the reader should consult a number of recent reviews on the field of oncolytic virotherapy as a whole. 1113 == Generation of oHSVs == Development of oHSVs involved initial deletion of a single viral gene and subsequently multiple viral gene deletions and modifications. Key examples of this development are discussed further. A summary of the viral genes modified in oHSVs and the functions of viral proteins encoded by Defactinib hydrochloride these genes is provided inTable 1 . A comprehensive list of deletion mutation oHSVs can be found inTable 2and altered gene regulation or receptor retargeted oHSVs inTable 3. == Table 1 . == Summary of viral genes modified in oHSVs Abbreviations: eIF2, elongation initiation factor 2; g, glycoprotein; HVEM, herpesvirus entry mediator; ICP, infected cell protein; MHC, major histocompatibility complex; oHSV, oncolytic herpes simplex virus; p, protein; PKR, protein kinase R; RL, repeat long; RS, repeat short; TAP, transporter associated with antigen processing; UL, unique long; US, unique short; VP, viral protein. == Table 2 . == Summary of oHSVs incorporating viral gene mutations Abbreviations: HSV-1, herpes simplex virus type 1; HSV-2, herpes simplex virus type 2; oHSV, oncolytic herpes simplex virus; p, protein; RL, repeat long; RS, repeat short; UL, unique long; US, unique short. == Table 3..
